RSS   Newsletter   Contact   Advertise with us
Post Online Media

Tony Coles elected to Regeneron board of directors

Tony ColesRegeneron Pharmaceuticals, Inc., a science-based biopharmaceutical company, announced that it has elected Tony Coles to its board of directors.
Article continues below

READ MORE CRISPR Therapeutics adds Tony Coles to board

Dr. Coles was nominated to become a member of the Regeneron Board by Sanofi.

Dr. Coles is Chairman and Chief Executive Officer of Yumanity Therapeutics, a company focused on transforming drug discovery for neurodegenerative diseases.

Previously, Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, an oncology-focused biopharmaceutical company, which was acquired by Amgen in 2012.

Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals.

Before joining NPS, Dr. Coles served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals.

He is a director of McKesson Corporation and Chairman of the Board of CRISPR Therapeutics. He is also a member of the board of trustees for Johns Hopkins Medicine.

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School.

He earned his M.D. from Duke University, a master's degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy